| SC 13G/A | 2019-05-09 | Opko Health, Inc. | MABVAX THERAPEUTICS HOLDINGS, INC. | 488,131 | 5.0% | EDGAR |
| SC 13G/A | 2019-04-10 | BlackRock Inc. | Opko Health, Inc. | 30,284,219 | 4.9% | EDGAR |
| SC 13D/A | 2019-03-22 | FROST PHILLIP MD ET AL | Opko Health, Inc. | 20,091,062 | 3.3% | EDGAR |
| SC 13D/A | 2019-03-20 | FROST PHILLIP MD ET AL | Opko Health, Inc. | 20,091,062 | 3.3% | EDGAR |
| SC 13D/A | 2019-03-13 | Opko Health, Inc. | VBI Vaccines Inc/BC | 6,678,751 | 6.8% | EDGAR |
| SC 13G/A | 2019-02-14 | Opko Health, Inc. | BioCardia, Inc. | 2,237,099 | 5.8% | EDGAR |
| SC 13G/A | 2019-02-14 | Opko Health, Inc. | NEOVASC INC | 3,361,298 | 9.1% | EDGAR |
| SC 13G/A | 2019-02-14 | Opko Health, Inc. | Cocrystal Pharma, Inc. | 2,659,685 | 8.9% | EDGAR |
| SC 13G | 2019-02-11 | VANGUARD GROUP INC | Opko Health, Inc. | 28,381,653 | 5.1% | EDGAR |
| SC 13G | 2019-02-08 | BlackRock Inc. | Opko Health, Inc. | 30,349,614 | 5.4% | EDGAR |
| SC 13D/A | 2018-11-20 | FROST PHILLIP MD ET AL | Opko Health, Inc. | 20,091,062 | 3.4% | EDGAR |
| SC 13D/A | 2018-11-20 | HSIAO JANE PH D | Opko Health, Inc. | 1,000,000 | 0.2% | EDGAR |
| SC 13G/A | 2018-02-14 | Opko Health, Inc. | NEOVASC INC | 5,063,841 | 9.9% | EDGAR |
| SC 13G/A | 2018-02-12 | Opko Health, Inc. | BioCardia, Inc. | 2,145,448 | 5.6% | EDGAR |
| SC 13G/A | 2018-02-12 | Opko Health, Inc. | RXi Pharmaceuticals Corp | 66,857 | 2.8% | EDGAR |
| SC 13G/A | 2018-02-02 | Opko Health, Inc. | Cocrystal Pharma, Inc. | 2,244,597 | 9.1% | EDGAR |
| SC 13D/A | 2017-12-27 | Opko Health, Inc. | Eloxx Pharmaceuticals, Inc. | 1,306,821 | 4.7% | EDGAR |
| SC 13D/A | 2017-11-14 | Opko Health, Inc. | Sevion Therapeutics, Inc. | 16,233,918 | 31.4% | EDGAR |
| SC 13D/A | 2017-11-01 | Opko Health, Inc. | VBI Vaccines Inc/BC | 6,678,752 | 16.6% | EDGAR |
| SC 13D/A | 2017-09-20 | Opko Health, Inc. | Opko Health, Inc. | 20,091,062 | 3.6% | EDGAR |